Category Archives: Pharmacotherapy

Advances in the pharmacotherapy: CONCLUSIONS(2)

A more rational selection of medications to improve behavioural disturbances in dementia will only be possible when we understand the mechanisms underlying these disorders. Current selection of medications is only empirical at best. One of the first steps in assessing … Continue reading

Advances in the pharmacotherapy: CONCLUSIONS(1)

More research is needed to investigate the mechanisms behind the neurodegeneration seen in AD. The disease is complex, and available treatments can only partially modify the cognitive and behavioural deficits. It appears that cholinergic enhancement (via cholinesterase inhibition and cholinergic … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(8)

Carbamazepine The therapeutic usefulness of the anticonvulsant carba-mazepine has been described in a number of uncontrolled studies . These reports demonstrate a response within two to four weeks with doses ranging from 100 to 1000 mg/day, and one open study … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(7)

Benzodiazepines Large controlled trials have been conducted with oxazepam ; however, most of these trials are outdated and, therefore, most of the participants did not undergo a standardized diagnostic work-up for dementia, and appropriate behavioural rating scales may not have … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(6)

Buspirone is a partial agonist of the serotonin receptor 5-HT1A and has been approved for the treatment of anxiety. Several open trials have shown that this medication may be beneficial for treating behavioural symptoms such as delusions, aggression and anxiety … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(5)

Selective serotonin reuptake inhibitors (SSRIs) are a group of antidepressants that have also been studied fortreating the agitated patient with dementia. Although initial case series have reported conflicting findings, two double-blind, placebo controlled trials have demonstrated encouraging results. In one … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(3)

A study conducted by Petrie et al is one of the few well done clinical trials in this area. In this double-blind, controlled, eight-week trial, haloperidol (mean dose 4.6mg/day) was compared with loxapine (mean dose 22mg/day) and placebo in 64 … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(2)

Antipsychotics Antipsychotics, or neuroleptics, are the most extensively studied and the most commonly used class of medications for this indication . Despite this, their effectiveness and safety have not been well confirmed, and prescribing techniques include randomly selecting one antipsychotic … Continue reading

Advances in the pharmacotherapy: PHARMACOTHERAPY OF BEHAVIOURAL DISORDERS IN DEMENTIA(1)

Certain behaviours are more responsive to treatment with medications. These behaviours include psychosis, depression, sleep disturbances, anxiety, aggression, agitation and sexual inappropriateness . In addition, patients may be more responsive to pharmacotherapeutic interventions during the early stages of AD, as … Continue reading

Advances in the pharmacotherapy: BEHAVIOURAL DISORDERS IN DEMENTIA

Behaviouraldisordersare a common feature associated with AD, and they complicate the management of patients with dementia. Behaviouraldisordershave been reported to occur in anywhere from 40% to 90% of patients with AD , in 36% to 64% of institutionalized patients and … Continue reading